SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&#34;Jaguar&#34; or the &#34;Company&#34;) today announced the voting results of the Company&#39;s Special Meeting of Stockholders held on April 20,

<p><strong id="dateline">SAN FRANCISCO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 20, 2026 / </strong><a rel="nofollow" href="https://pr.report/kt72">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/JAGX">JAGX</a>) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 20, 2026 (the "Special Meeting").</p><p>Five proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission on March 24, 2026. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at <a rel="nofollow" href="https://pr.report/kt74">http://www.sec.gov</a>. The proxy statement is also available on the Company's corporate website.</p><p><strong>About the Jaguar Health Family of Companies</strong></p><p>Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a rel="nofollow" href="https://pr.report/kt75">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.</p><p>For more information about:</p><p>Jaguar Health, visit <a rel="nofollow" href="https://pr.report/kt76"><u>https://jaguar.health</u></a></p><p>Napo Pharmaceuticals, visit <a rel="nofollow" href="https://pr.report/kt77"><u>napopharma.com</u></a></p><p>Napo Therapeutics, visit <a rel="nofollow" href="https://pr.report/kt78"><u>napotherapeutics.com</u></a></p><p>Magdalena Biosciences, visit <a rel="nofollow" href="https://pr.report/kt79">magdalenabiosciences.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p><strong>Contact:</strong></p><p><a rel="nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a></p><p>Jaguar-JAGX</p><p><strong>SOURCE:</strong> Jaguar Health, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-reports-approval-of-all-proposals-at-april-2026-special-1159025'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1159025" width="0" height="0"/>

JAGX

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

Jaguar Health Approves Strategic Proposals at 2026 Special Meeting

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&amp;#34;Jaguar&amp;#34; or the &amp;#34;Company&amp;#34;) today announced the voting results of the Company&amp;#39;s Special Meeting of Stockholders held on April 20,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Jaguar Health announced the approval of five strategic proposals during its April 2026 Special Meeting. These decisions, which reflect shareholder confidence, aim to bolster the company&#039;s focus on developing plant-derived pharmaceutical solutions, potentially enhancing its market position in gastrointestinal and mental health therapies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Jaguar Health approved five proposals at its April 2026 Special Meeting.</li><li>Proposals included governance changes and strategic plans for future growth.</li><li>Jaguar focuses on plant-derived drugs for gastrointestinal and mental health issues.</li><li>Stockholders can access detailed proposals via the SEC filings or company website.</li><li>No major financial estimates or new product launches announced.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Filament Health Corp. (FHM.V)</strong>: Involved in mental health initiatives through a joint venture with Jaguar.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This event falls under &#039;Corporate Developments&#039; as the proposals directly impact Jaguar&#039;s governance and strategic direction. These changes may set a foundation for future growth and market competitiveness.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Successful implementation of approved proposals could enhance Jaguar&#039;s market position.</li><li>Increased shareholder confidence may lead to a positive stock price reaction.</li><li>Further developments in Jaguar&#039;s gastrointestinal treatment options could drive sales growth.</li><li>Monitoring for updates on product pipeline and market strategies will be critical.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Five proposals approved at the Special Meeting on April 20, 2026.</li><li>Jaguar Health focuses on gastrointestinal and mental health drug development.</li><li>Company officially listed on NASDAQ under the symbol JAGX.</li><li>Proposals submitted detailed in SEC filings; public access allowed.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider JAGX for growth potential in plant-based pharmaceuticals in the near term.</p>
  </section>
</section>


<p><strong id="dateline">SAN FRANCISCO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 20, 2026 / </strong><a rel="nofollow" href="https://pr.report/kt72">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/JAGX">JAGX</a>) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 20, 2026 (the "Special Meeting").</p><p>Five proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission on March 24, 2026. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at <a rel="nofollow" href="https://pr.report/kt74">http://www.sec.gov</a>. The proxy statement is also available on the Company's corporate website.</p><p><strong>About the Jaguar Health Family of Companies</strong></p><p>Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a rel="nofollow" href="https://pr.report/kt75">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.</p><p>For more information about:</p><p>Jaguar Health, visit <a rel="nofollow" href="https://pr.report/kt76"><u>https://jaguar.health</u></a></p><p>Napo Pharmaceuticals, visit <a rel="nofollow" href="https://pr.report/kt77"><u>napopharma.com</u></a></p><p>Napo Therapeutics, visit <a rel="nofollow" href="https://pr.report/kt78"><u>napotherapeutics.com</u></a></p><p>Magdalena Biosciences, visit <a rel="nofollow" href="https://pr.report/kt79">magdalenabiosciences.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p><strong>Contact:</strong></p><p><a rel="nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a></p><p>Jaguar-JAGX</p><p><strong>SOURCE:</strong> Jaguar Health, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-reports-approval-of-all-proposals-at-april-2026-special-1159025'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1159025" width="0" height="0"/>

Jaguar Health announced the approval of five strategic proposals during its April 2026 Special Meeting. These decisions, which reflect shareholder confidence, aim to bolster the company's focus on developing plant-derived pharmaceutical solutions, potentially enhancing its market position in gastrointestinal and mental health therapies.

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News